Literature DB >> 17293017

Farnesyltransferase inihibitors in hematologic malignancies.

Jean-Luc Harousseau1.   

Abstract

Farnesyltransferase inhibitors (FTIs) inhibit certain cellular signal transduction pathways, and are being evaluated for activity in hematologic malignancies. Tipifarnib and lonafarnib are orally available FTIs that are active against a variety of targets and inhibit several pathways involved in the pathogenesis of hematologic malignancies. FTIs have demonstrated activity in a variety of hematologic diseases, including acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and multiple myeloma. This article reviews the clinical experience with tipifarnib and lonafarnib in the treatment of hematologic malignancies.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17293017     DOI： 10.1016/j.blre.2006.12.001

Source DB:  PubMed          Journal:  Blood Rev        ISSN： 0268-960X            Impact factor:   8.250


  11 in total

1.  Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.

Authors:  Husheng Ding; Jennifer S McDonald; Seongseok Yun; Paula A Schneider; Kevin L Peterson; Karen S Flatten; David A Loegering; Ann L Oberg; Shaun M Riska; Shengbing Huang; Frank A Sinicrope; Alex A Adjei; Judith E Karp; X Wei Meng; Scott H Kaufmann
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

Review 2.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

3.  Palmitoylation of oncogenic NRAS is essential for leukemogenesis.

Authors:  Benjamin Cuiffo; Ruibao Ren
Journal:  Blood       Date:  2010-03-03       Impact factor: 22.113

4.  Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.

Authors:  Husheng Ding; Jennifer Hackbarth; Paula A Schneider; Kevin L Peterson; X Wei Meng; Haiming Dai; Thomas E Witzig; Scott H Kaufmann
Journal:  Blood       Date:  2011-06-14       Impact factor: 22.113

5.  Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure.

Authors:  Masao Kaneki; Fumito Ichinose; Kazuhiro Shirozu; Shuichi Hirai; Tomokazu Tanaka; Shinsuke Hisaka
Journal:  Shock       Date:  2014-12       Impact factor: 3.454

6.  Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.

Authors:  Elliot Stieglitz; Ashley F Ward; Robert B Gerbing; Todd A Alonzo; Robert J Arceci; Y Lucy Liu; Peter D Emanuel; Brigitte C Widemann; Jennifer W Cheng; Nalini Jayaprakash; Frank M Balis; Robert P Castleberry; Nancy J Bunin; Mignon L Loh; Todd M Cooper
Journal:  Pediatr Blood Cancer       Date:  2014-12-08       Impact factor: 3.167

Review 7.  Targeted treatment and new agents in diffuse large B cell lymphoma.

Authors:  Sophie Dupire; Bertrand Coiffier
Journal:  Int J Hematol       Date:  2010-06-18       Impact factor: 2.490

8.  Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Authors:  Judith E Karp; Karen Flatten; Eric J Feldman; Jacqueline M Greer; David A Loegering; Rebecca M Ricklis; Lawrence E Morris; Ellen Ritchie; B Douglas Smith; Valerie Ironside; Timothy Talbott; Gail Roboz; Son B Le; Xue Wei Meng; Paula A Schneider; Nga T Dai; Alex A Adjei; Steven D Gore; Mark J Levis; John J Wright; Elizabeth Garrett-Mayer; Scott H Kaufmann
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

9.  Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.

Authors:  Fanqi Bai; Alejandro V Villagra; Jianxiang Zou; Jeffrey S Painter; Kirby Connolly; Michelle A Blaskovich; Lubomir Sokol; Said Sebti; Julie Y Djeu; Thomas P Loughran; Sheng Wei; Eduardo Sotomayor; Pearlie Epling-Burnette
Journal:  Cancer Immunol Immunother       Date:  2011-10-09       Impact factor: 6.630

10.  Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas.

Authors:  Kenneth A Field; Soratree Charoenthongtrakul; J Michael Bishop; Yosef Refaeli
Journal:  Mol Cancer       Date:  2008-05-19       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.